1. Home
  2. VRTX vs MELI Comparison

VRTX vs MELI Comparison

Compare VRTX & MELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • MELI
  • Stock Information
  • Founded
  • VRTX 1989
  • MELI 1999
  • Country
  • VRTX United States
  • MELI Uruguay
  • Employees
  • VRTX N/A
  • MELI N/A
  • Industry
  • VRTX EDP Services
  • MELI Catalog/Specialty Distribution
  • Sector
  • VRTX Technology
  • MELI Consumer Discretionary
  • Exchange
  • VRTX Nasdaq
  • MELI Nasdaq
  • Market Cap
  • VRTX 96.6B
  • MELI 103.8B
  • IPO Year
  • VRTX 1991
  • MELI 2007
  • Fundamental
  • Price
  • VRTX $423.53
  • MELI $2,159.17
  • Analyst Decision
  • VRTX Buy
  • MELI Strong Buy
  • Analyst Count
  • VRTX 26
  • MELI 18
  • Target Price
  • VRTX $491.78
  • MELI $2,799.17
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • MELI 552.8K
  • Earning Date
  • VRTX 11-03-2025
  • MELI 10-29-2025
  • Dividend Yield
  • VRTX N/A
  • MELI N/A
  • EPS Growth
  • VRTX N/A
  • MELI 46.70
  • EPS
  • VRTX 14.07
  • MELI 40.49
  • Revenue
  • VRTX $11,418,800,000.00
  • MELI $24,096,000,000.00
  • Revenue This Year
  • VRTX $10.92
  • MELI $38.23
  • Revenue Next Year
  • VRTX $9.55
  • MELI $26.17
  • P/E Ratio
  • VRTX $30.04
  • MELI $53.06
  • Revenue Growth
  • VRTX 10.46
  • MELI 35.81
  • 52 Week Low
  • VRTX $362.50
  • MELI $1,646.00
  • 52 Week High
  • VRTX $519.88
  • MELI $2,645.22
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 61.96
  • MELI 45.82
  • Support Level
  • VRTX $405.54
  • MELI $2,088.45
  • Resistance Level
  • VRTX $432.76
  • MELI $2,162.95
  • Average True Range (ATR)
  • VRTX 8.97
  • MELI 70.19
  • MACD
  • VRTX 1.62
  • MELI 6.12
  • Stochastic Oscillator
  • VRTX 71.05
  • MELI 53.53

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MELI MercadoLibre Inc.

MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

Share on Social Networks: